Hillstream Biopharma (NASDAQ:CNTN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Hillstream Biopharma (NASDAQ:CNTN) from a sell rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings lowered shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Hillstream Biopharma Price Performance

Shares of NASDAQ:CNTN opened at $2.14 on Friday. Hillstream Biopharma has a 1 year low of $1.75 and a 1 year high of $9.08. The company has a market capitalization of $170.52 million, a PE ratio of -4.28 and a beta of 1.45. The company has a 50 day moving average price of $2.36.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.